Is MORN a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Morningstar (MORN) rests on PitchBook and private-markets data: PitchBook is Morningstar's marquee growth asset, supplying data, analytics, and AI-enabled software across venture capital, private equity, private credit, and M&A. The bear case rests on credit-ratings revenue is cyclical and tracks debt-issuance volumes, so a slowdown in structured finance or corporate issuance can quickly pressure a fast-growing segment. Analysts covering it publish targets from $220.00 to $260.00 against a $207.37 price, so even the professionals disagree by 17% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Morningstar is an investment-research and financial-data provider whose products span five reportable segments: the Morningstar Direct Platform (data, research, Direct, and Advisor Workstation), PitchBook (private-capital data, analytics, and AI-enabled software for venture capital, private equity, private credit, and M&A), Morningstar Credit (credit ratings, research, and analytics through DBRS Morningstar), Morningstar Wealth (investment products, advisor platforms, and managed portfolios), and Morningstar Retirement. The business is built on proprietary datasets, independent research, and widely used ratings and indexes that embed deeply into advisor, asset-manager, and institutional workflows, giving it high switching costs and durable, largely recurring revenue. The investment picture centers on a shift in growth mix away from the mature core fund-research business toward faster-growing franchises. PitchBook continues to expand private-market data and AI features (in October 2026 it launched an agentic platform assistant and a PitchBook Data MCP for AI tools), Morningstar Credit has rebounded strongly with structured-finance and corporate ratings activity, and management has focused on margin discipline after a heavy investment period, which drove sharp operating-leverage gains in recent quarters. Revenue reached ~$663 million in the June 2026 quarter, up ~9.6% year over year, with adjusted EPS of ~$3.10 against a ~$2.83 consensus; trailing revenue is ~$2.57 billion and net income ~$422 million. The tradeoff is that revenue growth is high-single to low-double-digit rather than explosive, parts of the business are cyclical (ratings volumes track debt issuance, and license revenue tracks markets), and the stock reprices with both software and financial-data sentiment. At ~20x trailing and ~15x forward earnings and a market cap near ~$7.8 billion as of October 16, 2026, the shares price in steady growth plus continued margin recovery rather than a dramatic re-acceleration.
The bull case: what would have to be true for $260.00
The most optimistic published target on MORN is $260.00, +25.4% from the $207.37 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. PitchBook and private-markets data
PitchBook is Morningstar's marquee growth asset, supplying data, analytics, and AI-enabled software across venture capital, private equity, private credit, and M&A. As allocators push further into private markets and demand better data, PitchBook keeps adding users and expanding internationally, layering AI features onto a deep proprietary dataset. On October 14, 2026 it launched an agentic platform assistant and a PitchBook Data MCP that lets clients pull its data into their own AI assistants, a bet that distribution through AI tools adds to subscription value rather than replacing it.
2. Morningstar Credit (DBRS) rebound
The credit segment posted roughly 38% revenue growth in Q1 2026, led by structured finance and broader ratings activity. Credit is the most cyclical piece, tied to debt-issuance volumes, but a recovery in issuance and share gains in specific asset classes make it a swing factor for consolidated growth.
3. Margin expansion and operating leverage
After a period of heavy investment, Morningstar has prioritized cost discipline, which drove operating profit up more than 35% and diluted EPS up roughly 50% year over year in Q1 2026 on about 11% revenue growth. The second quarter kept the pattern, with adjusted EPS of ~$3.10 on ~9.6% revenue growth, and trailing operating margin now sits near ~24%. Consensus expects 2026 EPS of ~$12.37, up ~25%, so continued leverage on a largely fixed data-and-research cost base is central to the earnings story.
4. Recurring subscriptions and data moat
Much of Morningstar's revenue is recurring license and subscription income across Direct, Data, and Advisor Workstation, embedded in advisor and institutional workflows. Its widely cited ratings, indexes, and datasets create high switching costs and a durable base to cross-sell newer AI and analytics products into.
The bear case: what would have to be true for $220.00
The most pessimistic published target is $220.00, +6.1% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Morningstar is worth if the risks below bite instead of the drivers above.
Credit-ratings revenue is cyclical and tracks debt-issuance volumes, so a slowdown in structured finance or corporate issuance can quickly pressure a fast-growing segment. Core fund-research and license revenue is more mature and exposed to market levels and fee compression among asset-manager clients. Morningstar competes against far larger, better-capitalized data and index rivals (Bloomberg, S&P Global, MSCI, FactSet, LSEG, Moody's) that can bundle products and pressure pricing. AI and new fintech entrants could commoditize parts of the data and research business over time, a concern that weighed on financial-data stocks and left MORN roughly flat for 2026 despite rising earnings. Debt of ~$1.9 billion against ~$524 million of cash limits flexibility somewhat. The stock trades at a premium multiple to the market on trailing earnings, so any stall in PitchBook growth, credit volumes, or margin recovery can compress the valuation.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding MORN already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on MORN
3 analysts cover MORN, with an average target of $239.00 (+15.3% against $207.37) and a split of 2 buy, 1 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the MORN forecast and price target page.
How is MORN valued? (as of October 2026)
Snapshot for MORN as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$2.57B
- Q2 2026 revenue: ~$663M (up ~9.6% YoY)
- Q2 2026 adjusted EPS: ~$3.10 (vs ~$2.83 est.)
- Margins (TTM): ~62% gross, ~24% operating, ~16% net
- Net income (TTM): ~$422M
- P/E: ~20x trailing, ~15x forward
- Dividend yield: ~1.0% (~$2.00/share)
- Market cap: ~$7.8B
Morningstar has beaten adjusted EPS estimates in each of the last four quarters, and consensus sees ~25% EPS growth in 2026 and ~13% in 2027 on revenue rising toward ~$2.8 billion. At ~15x forward earnings and ~3x sales, the shares trade below larger index and ratings peers, a discount tied to slower top-line growth and AI-disruption worries around financial data. Third-quarter results are due October 28, 2026, with consensus near ~$3.04 of EPS on ~$665 million of revenue.
How do you decide if MORN is a buy?
Rather than asking whether MORN is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold MORN indirectly through an index or sector ETF before adding more.
What would change your mind on MORN
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: PitchBook and private-markets data stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: credit-ratings revenue is cyclical and tracks debt-issuance volumes, so a slowdown in structured finance or corporate issuance can quickly pressure a fast-growing segment fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the MORN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about MORN against your real portfolio and see your actual exposure before deciding.
Investing in Morningstar with AI
Connect the broker you already use and ask Walnut's AI how MORN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is MORN a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on PitchBook and private-markets data, with revenue (ttm) at ~$2.57B. The bear case rests on credit-ratings revenue is cyclical and tracks debt-issuance volumes, so a slowdown in structured finance or corporate issuance can quickly pressure a fast-growing segment. Analysts covering it are spread from $220.00 to $260.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell MORN?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Credit-ratings revenue is cyclical and tracks debt-issuance volumes, so a slowdown in structured finance or corporate issuance can quickly pressure a fast-growing segment. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $220.00, +6.1% from the $207.37 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for MORN?
+
PitchBook and private-markets data. PitchBook is Morningstar's marquee growth asset, supplying data, analytics, and AI-enabled software across venture capital, private equity, private credit, and M&A. The most optimistic analyst target on MORN is $260.00, +25.4% from the $207.37 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for MORN?
+
Credit-ratings revenue is cyclical and tracks debt-issuance volumes, so a slowdown in structured finance or corporate issuance can quickly pressure a fast-growing segment. Core fund-research and license revenue is more mature and exposed to market levels and fee compression among asset-manager clients. Morningstar competes against far larger, better-capitalized data and index rivals (Bloomberg, S&P Global, MSCI, FactSet, LSEG, Moody's) that can bundle products and pressure pricing. AI and new fintech entrants could commoditize parts of the data and research business over time, a concern that weighed on financial-data stocks and left MORN roughly flat for 2026 despite rising earnings. Debt of ~$1.9 billion against ~$524 million of cash limits flexibility somewhat. The stock trades at a premium multiple to the market on trailing earnings, so any stall in PitchBook growth, credit volumes, or margin recovery can compress the valuation. The most pessimistic published target is $220.00, +6.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Morningstar do?
+
Morningstar is an investment-research and financial-data provider whose products span five reportable segments: the Morningstar Direct Platform (data, research, Direct, and Advisor
What would have to change for MORN to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (PitchBook and private-markets data) stalling in the reported numbers rather than in the narrative, the risk above (credit-ratings revenue is cyclical and tracks debt-issuance volumes, so a slowdown in structured finance or corporate issuance can quickly pressure a fast-growing segment) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Morningstar do?
+
Morningstar is a financial-data and independent-research company. It sells investment data, research, ratings, indexes, and software to advisors, asset managers, and institutions across five segments: the Direct Platform, PitchBook, Morningstar Credit, Wealth, and Retirement.
What are Morningstar's business segments?
+
Its reportable segments are Morningstar Direct Platform (data and research tools), PitchBook (private-market data and analytics), Morningstar Credit (DBRS ratings and credit analytics), Morningstar Wealth (advisor platforms and managed portfolios), and Morningstar Retirement (retirement-plan products).
Is Morningstar profitable?
+
Yes. Morningstar is consistently profitable and generates significant free cash flow (about ~$498 million over the trailing twelve months). In Q1 2026 it reported operating profit up more than 35% and diluted EPS around $2.73, up roughly 50% year over year, and in Q2 2026 adjusted EPS of ~$3.10 beat the ~$2.83 consensus. Trailing net income is about ~$422 million.
Walnut is informational, not investment advice, and gives no verdict on MORN. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.